Resource impact statement
No significant resource impact is anticipated
NICE has recommended ofatumumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features only if the company provides ofatumumab according to the commercial arrangement.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
The use of ofatumumab is not expected to result in additional service requirements. It is self-administered at home via a pre-filled autoinjector pen (following initial healthcare professional guidance during the first injection), increasing convenience for people who use it and may save costs. The use of ofatumumab may also free up healthcare professional capacity compared to treatments administered by intravenous infusions in hospital. However, any savings as a result are not expected to be significant at a national level.
Ofatumumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact: Commercial.team@novartis.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: